Department of Respiratory, Jiyang People's Hospital of Jinan, Jinan City, 251400, Shandong Province, China.
Department of Comprehensive Medicine, Jiyang People's Hospital of Jinan, Jinan City, 251400, Shandong Province, China.
Appl Biochem Biotechnol. 2022 Dec;194(12):5862-5877. doi: 10.1007/s12010-022-04042-z. Epub 2022 Jul 14.
Lung cancer, one of the most often diagnosed malignancies, is the top cause of death in both men and women globally. In both developed and emerging countries, high incidences of cancer are becoming a huge health burden. Natural resources, including plants, have always been a possible source of lead compounds in the identification of optimal medications for cancer treatment, with natural resources accounting for around half of all anticancer drugs. Ruscogenin, a natural saponin, is a major component of Radix Ophiopogon japonicus with a well-established anticancer activity. In this study, the anticancer potential of ruscogenin against a B(a)P-challenged lung cancer model in mice was assessed. The mice were categorized into four groups: group I was as the control group, group II mice were challenged with B(a)P, group III rodents were treated with ruscogenin prior to challenge with B(a)P, and group IV rodents were treated with ruscogenin after B(a)P administration. Tumor incidence was calculated, and the following parameters were analyzed: body weight, lung weight, immunoglobulin (Ig) levels (IgG, IgA, and IgM), key marker enzymes, and proinflammatory cytokines in both treated and control mice. Lung tissues were analyzed via histopathological analysis. According to our results, all the markers that favor the growth of cancer were increased in the lung cancer group. After administration of ruscogenin, all the markers returned to their original levels, revealing the anticancer potential of ruscogenin.
肺癌是最常见的恶性肿瘤之一，是男性和女性全球死亡的主要原因。在发达国家和新兴国家，癌症发病率高正在成为一个巨大的健康负担。自然资源，包括植物，一直是寻找治疗癌症最佳药物的潜在先导化合物的来源，大约一半的抗癌药物来自自然资源。鲁斯可苷元是一种天然甾体皂苷，是麦冬的主要成分，具有明确的抗癌活性。在这项研究中，评估了鲁斯可苷元对 B(a)P 诱导的肺癌模型小鼠的抗癌潜力。将小鼠分为四组：第 I 组为对照组，第 II 组小鼠用 B(a)P 进行挑战，第 III 组小鼠在接受 B(a)P 挑战前用鲁斯可苷元进行治疗，第 IV 组小鼠在接受 B(a)P 治疗后用鲁斯可苷元进行治疗。计算肿瘤发生率，并分析以下参数：体重、肺重、免疫球蛋白（IgG、IgA 和 IgM）水平、关键标记酶和治疗及对照组小鼠中的促炎细胞因子。通过组织病理学分析对肺组织进行分析。根据我们的结果，肺癌组中所有促进癌症生长的标志物都增加了。鲁斯可苷元给药后，所有标志物均恢复到原来水平，显示出鲁斯可苷元的抗癌潜力。
